Buy & Sell Biogen Inc (BIIB) – Biogen Inc Price Today
Aura AI Summary
Key Stats
- $27.06BMarket Cap
- HealthSector
- -14.34%3M Drawdown
- $29.82BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 109 daysTypical Hold Time
Biogen Inc (BIIB) is currently valued at a market capitalization of $27.06B, with an enterprise value of $29.82B. Over the past 52 weeks, Biogen Inc has traded between a low of $116.82 and a high of $201.18, highlighting its annual price range. Over the past three months, Biogen Inc has recorded a drawdown of -14.34%, reflecting recent price volatility. On average, investors hold Biogen Inc for approximately 109 days, indicating typical investor behavior on the platform.
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
